Paras Healthcare allotment likely today: Check GMP, key details and how to check
Benchmarks Nifty22,589.50-10.5FEATURED FUNDS★★★★★UTI Aggressive Hybrid Fund Regular Plan-Growth5Y Return8.52 % Invest NowFEATURED FUNDS★★★★★Motilal Oswal Midcap Fund Direct-Growth5Y Return17.9 % Invest NowEnter search…
Paras Healthcare IPO allotment is expected to be finalised today after the Rs 1,450-crore issue was subscribed 2.23 times. With the GMP indicating a potential listing gain of around 1%, investors can check their allotment status on the MUFG Intime, NSE and BSE websites. The hospital chain is scheduled to list on October 28, 2026, after reporting a return to profitability in FY26.
Investors who subscribed to the Paras Healthcare IPO are awaiting the allotment status, which is expected to be announced today. The Rs 1,450-crore public issue received a moderate response, with overall subscription reaching 2.23 times, and applicants are now looking ahead to the company’s stock market debut.The IPO allotment is expected to be finalised today, allowing investors to check online whether they have received shares. Paras Healthcare shares are tentatively scheduled to list on the BSE and NSE on October 28, 2026.
Meanwhile, the IPO’s grey market premium (GMP) is hovering around 1%, indicating expectations of a modest listing gain. However, the GMP is an unofficial indicator of market sentiment and can fluctuate before listing. It does not guarantee the actual listing price or investor returns.
The IPO opened for subscription on October 21 and closed on October 23, 2026. It was subscribed 2.23 times overall.
The retail investor portion was subscribed 2 times, while the qualified institutional buyers (QIBs) category saw 3.09 times subscription. The non-institutional investor (NII) segment was subscribed 0.66 times, or 66%.
Live Events
The Rs 1,450-crore IPO comprises a fresh issue of 72.15 lakh shares aggregating to Rs 500 crore and an offer for sale (OFS) of 1.37 crore shares worth Rs 950 crore.
Paras Healthcare had fixed the price band at Rs 660–693 per share, with a lot size of 21 shares. At the upper end of the price band, retail investors applying for one lot need to invest a minimum of Rs 14,553.
JM Financial Ltd., BofA Securities India Ltd. and Nuvama Wealth Management Ltd. are the book-running lead managers for the issue, while MUFG Intime India Pvt. Ltd. is the registrar.
Investors can verify their allotment through either of the following platforms:
1. Registrar’s Website
- Visit the MUFG Intime India IPO allotment page (https://in.mpms.mufg.com/Initial_Offer/public-issues.html)
- Select Paras Healthcare from the drop-down menu.
- Enter your PAN, application number, or DP/Client ID.
- Click Submit to view your allotment status.
2. NSE Website (https://www.nseindia.com/invest/check-trades-bids-verify-ipo-bids)
- Go to NSE IPO Allotment page
- Select Equity
- Choose Paras Healthcare
- Enter your application number and PAN.
3.BSE Website ( https://www.bseindia.com/investors/appli_check)
- Select Equity under issue type.
- Select Paras Healthcare from the dropdown.
- Enter your application number OR PAN number.
- And fill the captcha and click search to view allotment.
IPO Objects of the Issue
The company plans to utilise Rs 320.90 crore from the net proceeds of the IPO to prepay or repay, either fully or partially, certain outstanding borrowings availed by the company. Additionally, Rs 54.10 crore will be invested in its wholly owned subsidiary, PMHPL, which operates a hospital in Srinagar, to facilitate the full or partial repayment or prepayment of its outstanding borrowings.The remaining proceeds will be allocated towards general corporate purposes. Of the total IPO proceeds of Rs 375 crore, the primary objective is to reduce the company's debt burden, strengthen its financial position and support its overall corporate requirements.
Financials Performance
Paras Healthcare Ltd. reported a 24% year-on-year increase in total income to Rs 1,629 crore in FY26, compared with Rs 1,314 crore in FY25. The company also turned profitable, posting a profit after tax (PAT) of Rs 44 crore in FY26, against a loss of Rs 58 crore in the previous financial year.About Paras Healthcare
Incorporated in 1987, Paras Healthcare Limited is a leading clinical speciality-led hospital platform providing tertiary and quaternary healthcare services across North India, Bihar, and Jharkhand under the "Paras Health" brand. The company operates eight hospitals with an aggregate bed capacity of 2,211 beds across Gurugram, Panchkula, Patna, Darbhanga, Kanpur, Udaipur, Ranchi, and Srinagar as of June 30, 2026.It specialises in cardiac sciences, oncology, neurosciences, gastro sciences, orthopaedics & sports injury, and renal sciences (CONGOR specialities), which contributed 75.30% of revenue in Fiscal 2026. Paras Healthcare has over 20 years of operating history and follows a balanced growth strategy through mature, emerging, and new hospitals. The company plans to expand its network with a 300-bed hospital in Gurugram and a 500-bed hospital in Ludhiana, increasing total capacity to 3,011 beds by March 2028. As of March 31, 2026, it had 4,670 employees, including 1,084 doctors and 1,937 nurses.
Disclaimer: The views/recommendations mentioned in this article, wherever applicable, are those of the respective SEBI-registered Research Analyst/brokerage and have been reproduced/reported with due attribution. They should not be construed as the views or recommendations of The Economic Times Digital or the journalist. Readers are advised to consider the original research report and make their investment decisions based on their own assessment. Brokerage disclaimers here
Add as a Reliable and Trusted News Source Add Now!
(You can now subscribe to our ETMarkets WhatsApp channel)
Read More News onParas Healthcare IPOParas Healthcare IPO allotment statusParas Healthcare GMPParas Healthcare IPO listing dateParas Healthcare IPO subscriptionParas Healthcare share priceParas Healthcare IPO allotment dateParas Healthcare financial resultsParas Healthcare IPO status checkParas Healthcare IPO listing gain
(What's moving Sensex and Nifty Track latest market news, stock tips, Budget 2025, Share Market on Budget 2025 and expert advice, on ETMarkets. Also, ETMarkets.com is now on Telegram. For fastest news alerts on financial markets, investment strategies and stocks alerts, subscribe to our Telegram feeds .)
Top Trending Stocks: SBI Share Price, Axis Bank Share Price, HDFC Bank Share Price, Infosys Share Price, Wipro Share Price, NTPC Share Price
...moreless(You can now subscribe to our ETMarkets WhatsApp channel)
Read More News onParas Healthcare IPOParas Healthcare IPO allotment statusParas Healthcare GMPParas Healthcare IPO listing dateParas Healthcare IPO subscriptionParas Healthcare share priceParas Healthcare IPO allotment dateParas Healthcare financial resultsParas Healthcare IPO status checkParas Healthcare IPO listing gain
(What's moving Sensex and Nifty Track latest market news, stock tips, Budget 2025, Share Market on Budget 2025 and expert advice, on ETMarkets. Also, ETMarkets.com is now on Telegram. For fastest news alerts on financial markets, investment strategies and stocks alerts, subscribe to our Telegram feeds .)
Top Trending Stocks: SBI Share Price, Axis Bank Share Price, HDFC Bank Share Price, Infosys Share Price, Wipro Share Price, NTPC Share Price
...morelessPrime ExclusivesInvestment IdeasStock Report PlusePaperWealth EditionWill oil turn into a lingering problem? Is the world economy, India, or the market prepared?
KYB and KYC: Business behind the wealth creator called ‘Divi’s Lab’ – Part 2, concluding
KYB and KYC: Business behind the wealth creator called “Divi’s Lab” – Part 1
The global business of promising more
One company, 2 words. Bond yield and CDS: Will they decide the fate of global markets?
Business of Odd Things: Inside an industry that farms fish that nobody is meant to eat
- 1
- 2
- 3
& personalised newslettersLogin NowUnlimited AccessStarting @ Rs120/monthGet access to exclusive stories, expert opinions &
in-depth stock reportsSubscribe NowET
Unlock Access to All Exclusives with ETPrime FREE TRIAL
15 Days Free: Unlock All ETPrime Exclusives, Market Tools & ePapers
Trial offer expiring in00 : 05 : 00
I'd rather pay ₹2599 nowUh-oh! This is an exclusive story available for selected readers only.
Worry not. You’re just a step away.
Prime Account Detected!
It seems like you're already an ETPrime member with
Login using your ET Prime credentials to enjoy all member benefits
Log out of your current logged-in account and log in again using your ET Prime credentials to enjoy all member benefits.
Unlock ETPrime's Exclusive Stories Today!
Big Price Drop! Flat 40% Off
Student Only OfferAlready a Member? Sign In nowAlready a Member? Sign In nowAlready a Member? Sign In nowOffer Exclusively For You
Save up to Rs. 700/-
ON ET PRIME MEMBERSHIP
Avail OfferOffer Exclusively For You
Get 1 Year Free
With 1 and 2-Year ET prime membership
Avail OfferOffer Exclusively For You
Get 1 Year Free
With 1 and 2-Year ET prime membership
Avail OfferOffer Exclusively For You
Get Flat 40% Off
Then ₹ 1749 for 1 year
Avail OfferOffer Exclusively For You
ET Prime at ₹ 49 for 1 month
Then ₹ 1749 for 1 year
Avail OfferSpecial Offer
Get flat 40% off on ETPrime
Avail OfferAvail OfferClaim NowAlready a Member? Sign In nowNeed Assistance?
Connect with an ETPrime expert for personalized support and guidance
+91 9484700004'; }); } if(listing) { var h3 = "You tried reading " + listArr.length + " locked stories in the past " + threshold + " days.", h4 = "Become an ET Prime member and don't miss out on these exclusive stories."; var html = '' + h3 + '
' + h4 + '
- ' + listing + '
What’s Included with
ETPrime Membership
1Exclusive Insights That Matter
Uncover the truth with our investigative stories
Make strategic moves using the real-world case studies
Read industry-specific stories to identify emerging trends
Spot opportunities with in-depth insights that matter
Trump temper on H-1B visas is forcing Indians to do these things to stay put in US
What Adani’s US indictment means for India Inc’s overseas fundraising
Why veterans like Reliance, L&T are on acquisition spree? Aswath Damodaran has an answer.
Will China’s dollar bond sale in Saudi Arabia trump the US in financial world?
Huawei launches its own OS to compete with Google and Apple. But can it win beyond China?
The problem with lab grown diamonds
Why a falling rupee is a better option for the economy
A list of top 20 momentum stocks that have delivered massive returns in one year
2Invest Wisely With Smart Market Tools & Investment Ideas
Alpha Trade
Get daily trade ideas from SEBI-registered research analysts.
Investment Ideas
Grow your wealth with stock ideas & sectoral trends.
Stock Reports Plus
All-in-one stock research with Stock Score, peer comparison & key signals.
BigBull Portfolio
Get to know where the market bulls are investing to identify the right stocks.
Stock Analyzer
Check the score based on the company's fundamentals, solvency, growth, risk & ownership to decide the right stocks.
Market Mood
Analyze the market sentiments & identify the trend reversal for strategic decisions.
Stock Talk Live at 9 AM Daily
Ask your stock queries & get assured replies by ET appointed, SEBI registered experts.
3Stay informed anytime, anywhere with ET ePaper
ePaper - Print View
Read the PDF version of ET newspaper. Download & access it offline anytime.
ePaper - Digital View
Read your daily newspaper in Digital View & get it delivered to your inbox everyday.
Wealth Edition
Manage your money efficiently with this weekly money management guide.
TOI ePaper
Read the PDF version of TOI newspaper. Download & access it offline anytime.
Deep Explainers
Explore the In-depth explanation of complex topics for everyday life decisions.
Health+ Stories
Get fitter with daily health insights committed to your well-being.
Personal Finance+ Stories
Manage your wealth better with in-depth insights & updates on finance.
5Enjoy Complimentary Subscriptions From Top Brands
Stream new documentaries from all across the world every day.
Stories you might be interested in
Figures reflect the source report and its stated period. This article is for information and is not investment advice.
